Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.

ABSTRACT:

Background

Highly sensitive molecular assays have been developed to detect plasma-based circulating tumor DNA (ctDNA), and emerging evidence suggests their clinical utility for monitoring minimal residual disease and recurrent disease, providing prognostic information, and monitoring therapy responses in patients with solid tumors. The Invitae Personalized Cancer Monitoring^™ assay uses a patient-specific, tumor-informed variant signature identified through whole exome sequencing to detect ctDNA in peripheral blood of patients with solid tumors.

Methods

The assay's tumor whole exome sequencing and ctDNA detection components were analytically validated using 250 unique human specimens and nine commercial reference samples that generated 1349 whole exome sequencing a

SUBMITTER: Zhao J 

PROVIDER: S-EPMC10590345 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature